In contrast to healthy subjects, the so-called incretin effect is substantially reduced or even absent in patients with type 2 diabetes (T2DM) (1), making the GLP-1 receptor (GLP-1R) an attractive target for antidiabetic treatment, using GLP-1 receptor agonists (GLP-1RAs). Here, GLP1R is linked to type 2 diabetes mellitus.